GlassScriptPhysician profile
Seth J Richter
NPI 1780670323
$9,732.07
in general payments reported to CMS, 2019-2025
26 companies · $3,095 in 2025
The $3,095 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $857 · 2021: $650 · 2022: $1,224 · 2023: $1,689 · 2024: $2,115 · 2025: $3,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,656 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,655.80 |
| Education | $242.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,612.27 | 2019-2025 | |
| Janssen Biotech, INC. | $1,396.45 | 2022-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $896.45 | 2021-2025 | Epclusa |
| Cook Biotech Incorporated | $725.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $538.10 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $398.57 | 2019-2025 | Xifaxan |
| Ambu INC. | $374.35 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $367.23 | 2022-2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $335.91 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $320.59 | 2023-2025 | Dupixent |
| Celgene Corporation | $281.78 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $244.21 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $216.71 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $183.41 | 2023 | Rebyota |
| Medtronic, INC. | $157.68 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $130.46 | 2022 | |
| Madrigal Pharmaceuticals | $130.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Mallinckrodt Hospital Products INC. | $123.35 | 2025 | Terlivaz |
| Genzyme Corporation | $82.67 | 2024-2025 | |
| Pfizer INC. | $52.17 | 2019-2021 | |
| Celltrion USA INC. | $47.87 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $40.20 | 2025 | Omvoh |
| Cook Medical LLC | $38.37 | 2021 | |
| Boston Scientific Corporation | $13.77 | 2023 | Resolution 360 Clip |
| Apollo Endosurgery US INC | $12.60 | 2021 | |
| Lucid Diagnostics INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Richter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.